Company intelligence
Scribe Therapeutics
CRISPR by Design™
Biotechnology Research
Alameda, US
90 employees
9 public signals
About Scribe Therapeutics
Scribe Therapeutics is pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives.
Verified activity
Signals from Scribe Therapeutics
9 published signals
People
Scribe Therapeutics is hiring a Director of Investor Relations to lead Scribe's growth as a public company through education and communication.
Reported by Scribe Therapeutics
Research & Knowledge
Scribe Therapeutics received awards from the California Institute for Regenerative Medicine (CIRM) totaling more than $25 million to advance its gene editing programs STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry.
Reported by Scribe Therapeutics
Research & Knowledge
Scribe Therapeutics published a manuscript on ELXR, its highly engineered epigenetic silencing technology.
Reported by Scribe Therapeutics
Products & Services
Scribe Therapeutics initiated a first-in-human Phase 1 clinical trial for its in vivo epigenetic silencing therapy STX-1150.
Reported by Scribe Therapeutics
Capital & Finance
Scribe Therapeutics completed its initial public offering in the first half of 2029.
Reported by Scribe Therapeutics
Presence & Recognition
Scribe Therapeutics management team will participate in the Wells Fargo Healthcare Conference in Boston on Sept. 9, 2026, the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, 2026, and the Cell & Gene Meeting on the Mesa in Phoenix on Oct. 5, 2026.
Reported by Scribe Therapeutics
Research & Knowledge
Scribe Therapeutics launched an office tour series where scientists sit down with leaders to dig into their latest findings.
Reported by Benjamin Oakes
Research & Knowledge
Scribe Therapeutics co-founder David Savage spoke with Scribe co-founder David Savage about a new study co-led by Maria Lukarska and Luke Oltrogge examining the activity specificity spectrum of adenine base editors.
Reported by Benjamin Oakes
Presence & Recognition
Scribe Therapeutics co-founders David Savage and Benjamin Oakes sat down for an Office Hours session to break down groundbreaking research on base editing precision and safety in genetic medicines.
Reported by Andrew Meadows